demcizumab
mAbexperimental
Demcizumab is a humanized monoclonal antibody which is used to treat patients with pancreatic cancer or non-small cell lung cancer. Demcizumab has completed phase 1 trials and is currently undergoing phase 2 trials. Demcizumab was developed by OncoMed Pharmaceuticals in collaboration with Celgene. — Wikipedia
Clinical trial activity
8 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2008 (NCT00744562)
Timeline
Indications
Mechanism of action
- Delta-like protein 4INHIBITOR
DLL4 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDemcizumab ↗
- ChEMBLCHEMBL2109384 ↗
Also known as
- demcizumab
- demcizumab
- demcizumab
- demcizumab
- omp-21m18
- omp-21m18
- omp-21m18
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02722954 | Phase 1 | Jan 1, 2016 | Celgene, Mereo BioPharma |
| NCT02289898 | Phase 2 | Apr 20, 2015 | Celgene, Mereo BioPharma |
| NCT02259582 | Phase 2 | Dec 1, 2014 | Celgene, Mereo BioPharma |
| NCT01952249 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2013 | Mereo BioPharma |
| NCT01189968 | Phase 1 | Sep 1, 2010 | Mereo BioPharma, Novotech |
| NCT01189942 | Phase 1 | Sep 1, 2010 | Mereo BioPharma, Novotech |
| NCT01189929 | Phase 1 | Aug 1, 2010 | Mereo BioPharma, Novotech |
| NCT00744562 | Phase 1 | Aug 1, 2008 | Mereo BioPharma |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mereo BioPharma | For profit | 8 | 8 | 2 | 2008 |
| Celgene | For profit | 3 | 0 | 2 | 2014 |
| Novotech | For profit | 3 | 0 | 1 | 2010 |
3 organizations
Page 1 / 1